MAM
LOGC

Meeder Asset Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Meeder Asset Management’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-379
Closed -$1K – 2613
2020
Q1 		$1K Buy
+379
New +$2.95K ﹤0.01% 2267

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Meeder Asset Management's LOGC Position: Q2 2020 in Review

Meeder Asset Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2020, closing a stake of 379 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in LOGC in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 43 funds tracked by Wall St. Rank hold LOGC as of Q2 2020.

  • Meeder Asset Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 379 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $1K.
  • Meeder Asset Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Meeder Asset Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $1K in Q1 2020.
  • 43 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.